Mitochondrial neurogastrointestinal encephalomyopathy is a rare autosomal recessive disorder characterized by severe muscle wasting, gastrointestinal dysmotility, leukoencephalopathy, peripheral neuropathy, and ophthalmoplegia. The pathogenesis involves the accumulation of very high concentrations of nucleosides dThd and dUrd along with depletion of nucleotide dCTP. One of the treatment measures is the removal of nucleosides dThd and dUrd by hemodialysis and peritoneal dialysis. Only a few patient reports of dialysis as a measure to remove nucleosides had been reported.
Introduction
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare autosomal recessive disorder characterized by severe muscle wasting, gastrointestinal dysmotility, leukoencephalopathy, peripheral neuropathy, and ophthalmoplegia. [1] The mutations in the TYMP gene encoding thymidine phosphorylase (TP) cause alterations in the respiratory chain and mitochondrial DNA (mtDNA). [2] The prognosis of this disease is limited; most patients die by the age of 35 years, but survival may range from 15 to 54 years. [1] 
Case Report
A 20-year-old male patient had normal birth history and milestones until 2 years of age. Delayed milestones appeared from the 3 rd year along with failure to thrive. There was no mental retardation or cognitive impairment at any time. There were no seizures, gait abnormalities, bowel or bladder disturbances, or visual and hearing difficulties. At 10 years of his age, he had acute abdomen for which appendicectomy was done. However, the abdominal pain recurred frequently. The abdominal pain in the beginning was one or two episodes a week; later before, he attained the age of 16 years it worsened to more than 5-10 episodes a day. He also developed early Cardiovascular and respiratory system was unremarkable. External genitalia showed both descended testes in the scrotum with no pubic hair. Penis was small with normal external meatus and normal glans. Axillary hair, beard, and moustache were absent.
He was admitted to neurology department after he had one episode of convulsion. On magnetic resonance imaging (MRI) brain, T2 signal hyperintensities were seen involving in both frontal, temporal, parietal, and occipital lobes along with pons and both cerebellar hemispheres. [ Figure 3 ] As these features were indicated a mitochondrial leukoencephalopathy, the possibility of MNGIE was suspected. He was further evaluated by gene sequencing for TYMP gene, the culprit gene for MNGIE. On gene sequencing, a frameshift mutation along with deletion of exon 4 was noted, which is novel mutation in TYMP gene and hence establishing the diagnosis of MNGIE. Serum levels of thymidine or deoxyuridine were not done.
After the diagnosis of MNGIE, the possible treatment options were discussed with the parents of the patient. Laparoscopic peritoneal dialysis (PD) catheter placement was done by the surgical gastroenterologist. PD was started after 2 weeks of patient training. He was prescribed one 8 h overnight dwell with 1.5% dextrose of 600 mL volume (30 mL/kg). There were no mechanical complications or peritonitis to date. After 2 months, the patient had improvement in appetite. Postprandial vomiting disappeared completely. Abdominal pain frequency decreased from daily to once or twice a fortnight. His weight increased from 18 to 21.5 kg. Numbness in peripheries vanished completely. However, his mid-arm circumference remained unchanged. Ophthalmoplegia and MRI brain changes remained the same.
Initially, the only one exchange was prescribed; as the patient showed clinical improvement, we advised three exchanges per day. At present three 6 h exchanges of 600 mL, each was being done. The fill volume, however, could not be increased as the tense abdomen could not be tolerated and breathlessness was experienced, probably due to splinting of weak diaphragm and atrophied intercostals and negligible accessory respiratory muscles. We could not test the serum or PD fluid levels of nucleosides. It is not done in any laboratory in India. The patient is under regular monthly follow-up with our facility.
Discussion
MNGIE is a progressive metabolic disorder caused by the cytosolic enzyme thymidine phosphorylase deficiency. TP is coded by TYMP gene (previously ECGF1) which is located on chromosome 22q13.33. TP is seen in almost all human tissues such as gastrointestinal, central, and peripheral nervous system, spleen, liver, urinary bladder, leukocytes, and platelets. [3] TP is absent in kidneys, aorta, and adipose tissue and minimal in muscles. The pathogenesis involves the accumulation of very high concentrations of nucleosides dThd and dUrd along with depletion of nucleotide dCTP. [4] This leads to an imbalance in nucleotide versus nucleoside levels, which results in the destabilization of mtDNA. [5] [ Figure 4 ] This causes interference with mtDNA repair and replication ultimately leading to cell death by apoptosis.
The estimated rate of occurrence is 1-9:1,000,000, [6] and as of 2011, fewer than 200 patients have been described in the medical literature. [7] The natural history of MNGIE is a relentless progression of the disease which invariably culminates in death with severe asthenia and infections being the most common causes of death. Most patients display typical MNGIE features by the age of 20 years. [8, 9] Gastrointestinal symptoms are the earliest to appear. [1] Ocular manifestations and sensory neuropathy in the form of numbness are the second most common manifestations. The treatment includes measures such as fat-soluble vitamin supplementation, levocarnitine, exercise therapy, symptomatic therapy for pain abdomen and vomiting, celiac plexus blockade for severe/recurrent abdominal pain, removal of nucleosides dThd and dUrd by hemodialysis and PD, enzyme replacement therapy, hematopoietic stem cell transplantation (HSCT), and gene therapy.
Only a few patient reports of dialysis as a measure to remove nucleosides had been reported. Spinazzola et al. [10] first reported the hemodialysis in two patients of MNGIE. Patient A underwent one dialysis and patient B underwent three consecutive weekly dialysis treatments. Hemodialysis reduced circulating concentrations of thymidine in both patients. However, the effect was transient. Three hours after dialysis, levels of the nucleoside returned to pretreatment values. Repetitive hemodialysis was also done to maintain basal levels of nucleosides in blood. [11] Yavuz et al. [12] first reported PD in MNGIE. Patient received PD for 3 years. An immediate improvement in gastrointestinal symptoms observed and also weight gain was noted. However, no change in ocular and neurological symptoms had been observed. In another report, the PD was continued for 15 months. [13] An improvement in gastrointestinal symptoms and mitigation of numbness in hands and legs observed; eventually, the patient underwent heterologous HSCT.
In MNGIE, the serum levels of thymidine and deoxyuridine are increased logarithmically and it happens every day. Furthermore, the urinary excretion is saturable in the light of very high serum levels. In this situation, even a small reduction in the serum levels by increasing the clearance by a mere 500 mL/day might allow the imbalance between nucleoside pools to come down, by reversing the reaction catalyzed by TP and favoring the salvage pathway, which allows better mtDNA function in various cell locations. [10] As this change is not always measurable, this may not reflect as serum level changes yet making clinical improvement. The dissociation between clinical improvement and laboratory measurements had been reported before. [12] This leads us to answer a second logical question that has arisen from the above explanation, how the PD improves neurologic and ophthalmology clinical features notwithstanding the blood-brain barrier to the clearance of nucleosides from cerebrospinal fluid? The explanation stems from the work of Yavuz et al. [12] who had similar observations where there was no demonstrable change in serum levels of nucleosides after a day long PD. The nucleoside concentrations in the dialysate were on average one-third of plasma levels (approximately 100 μmol of both thymidine and deoxyuridine was removed daily by PD). In the same observation, improvement of symptoms occurred in the face of unchanged serum levels of nucleosides which means in addition to high serum nucleoside levels, and pathogenesis of MNGIE involves other yet to be explained mechanisms which might be addressed through PD. In a report published by Sivadasan et al., similar results were seen with resolution of symptoms after starting on PD and return of symptoms when the patient stopped PD which again regressed with PD reinitiation. [14] One proposed mechanism of pathogenesis of MNGIE is that it is the nucleoside accumulation and subsequent reduction of dCTP nucleotides, rather than the deficiency of TP per se, that account for the molecular and phenotypic alterations in MNGIE. [15] In our patient, the reason for no improvement of ophthalmoplegia and brain changes appeared. Once the neurons of central nervous system (CNS) were damaged, the regrowth was almost unlikely. As glial cells replaced the dead neurons, even if the root cause was corrected, the CNS changes seldom reversed. This was evident in previous observations by Ariaudo et al. [13] MNGIE is often missed due to its extremely variable presentation from being an acute abdomen to slow relentless wasting disorder and hence needs a very high index of suspicion for diagnosis. A nephrologist has a more promising role in the form of dialysis. Given the limited and difficult treatment options, PD should be considered as a viable and potential treatment option because it obviates the need for vascular access and provides independence to the patient. PD can be used for improving the general condition of the patient when HSCT is anticipated. None of the treatment options available currently have shown to increase the life span of these patients.
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